CollPlant Biotechnologies (CLGN) Return on Sales [ROS] (2017 - 2026)
CollPlant Biotechnologies (CLGN) posted Return on Sales [ROS] of 8206.48% for the quarter ended Jun 30, 2026, up 6431.06 percentage points from 1775.42% a year earlier and up 12473.60 percentage points from the prior quarter.
CollPlant Biotechnologies (CLGN) Return on Sales [ROS] (2017 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at CollPlant Biotechnologies was -285.85%, up 4.99 percentage points year-over-year; for the year ended Dec 31, 2025, it was -484.31%, up 2865.40 percentage points from the prior year.
- Annual Return on Sales [ROS] shows a five-year change of -393.08 percentage points (years ended Dec 2020 to Dec 2025).
- In prior years, CollPlant Biotechnologies' Return on Sales [ROS] was -3349.71% in the year ended Dec 31, 2024 (-3281.16 pp), -68.55% in the year ended Dec 31, 2023 (+5649.51 pp), -5718.06% in the year ended Dec 31, 2022 (-5718.48 pp) and 0.42% in the year ended Dec 31, 2021 (+91.65 pp).
- The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Return on Sales [ROS] in data going back to the quarter ended Dec 31, 2017.
- On a year-over-year basis, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of +43.16 percentage points.
- The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was the quarter ended Sep 30, 2025, with a gain of 108995.45 percentage points; the weakest was the quarter ended Sep 30, 2024, with a drop of 102847.67 percentage points.
- According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -4267.12% (quarter ended Mar 30, 2026), -5250.00% (quarter ended Dec 31, 2025) and -4554.55% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | CollPlant Biotechnologies | 4.38 Mn | -25.06 Mn | -456,000.00 | 8,206.48% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8,206.48% |
| Mar 30, 2026 | -4,267.12% |
| Dec 31, 2025 | -5,250.00% |
| Sep 30, 2025 | -4,554.55% |
| Jun 30, 2025 | 1,775.42% |
| Mar 30, 2025 | -80.19% |
| Dec 31, 2024 | -2,423.17% |
| Sep 30, 2024 | -113,550.00% |
| Jun 30, 2024 | 1,769.48% |
| Mar 31, 2024 | 4,417.35% |
| Dec 31, 2023 | -1,694.98% |
| Sep 30, 2023 | -10,702.33% |
| Jun 30, 2023 | 55.74% |
| Mar 31, 2023 | 812.70% |
| Dec 31, 2022 | -8,062.07% |
| Sep 30, 2022 | -4,099.08% |
| Jun 30, 2022 | -6,340.91% |
| Dec 31, 2021 | -1,227.10% |
| Sep 30, 2021 | -2,210.00% |
| Jun 30, 2021 | -443.27% |
CollPlant Biotechnologies Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "CLGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();